Vancomycin
Vancomycin Price range: $ 122,00 through $ 399,00
Back to products
Viagra Black
Viagra Black Price range: $ 47,00 through $ 397,00

Veltride

Price range: $ 22,00 through $ 57,00

Veltride is a highly effective medication specifically formulated to treat the symptoms of benign prostatic hyperplasia (BPH) in men. Its active ingredient, Dutasteride, works by reducing the production of hormones that cause the prostate gland to enlarge. By consistently shrinking the prostate, this treatment helps improve urinary flow and eases the discomfort associated with an enlarged prostate. It also plays a crucial role in lowering the risk of acute urinary retention and the potential need for prostate surgery. Veltride provides a reliable solution for managing BPH, helping men maintain better urinary health and a more comfortable lifestyle.

Active substance: Dutasteride
SKU: Veltride Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Veltride belongs to a class of medications known as 5-alpha reductase inhibitors, containing the active substance dutasteride. It is prescribed for the treatment of symptomatic benign prostatic hyperplasia (BPH) in adult men to improve lower urinary tract symptoms, reduce prostate volume, and lower the risk of acute urinary retention and BPH-related surgery.

As a prescription-only drug regulated under federal safety standards, Veltride must be taken strictly under medical supervision. Therapeutic decisions require thorough baseline evaluation, including prostate-specific antigen assessment and monitoring of cardiovascular and hepatic status.

Parameter Specification
Active Ingredient (INN) Dutasteride
Therapeutic Class 5-Alpha Reductase Inhibitor
Dosage Form Oral capsule / tablet
Route of Administration Oral
Primary Indication Benign Prostatic Hyperplasia (BPH)
Prescription Status Prescription (Rx) only

Main uses

Veltride is indicated primarily for the management of symptomatic benign prostatic hyperplasia (BPH) in adult men with an enlarged prostate. Clinical goals include alleviating lower urinary tract symptoms such as weak urine stream, hesitation, urinary frequency, and nighttime awakening (nycturia). In clinical settings, long-term administration decreases the overall risk of acute urinary retention (AUR) and reduces the necessity for surgical interventions such as transurethral resection of the prostate (TURP). Any potential use for androgenic alopecia (male pattern hair loss) is considered off-label and is not approved under standard FDA labeling for this specific formulation. Off-label prescribing must be explicitly evaluated by a licensed healthcare provider based on individual patient parameters.

How the drug works

The mechanism of action of Veltride relies on the competitive and specific inhibition of both Type 1 and Type 2 isoforms of 5-alpha reductase. This intracellular enzyme is responsible for converting circulating testosterone into 5-alpha-dihydrotestosterone (DHT), the primary androgen responsible for prostatic growth and enlargement. By blocking both isoenzymes, dutasteride suppresses serum DHT concentrations by more than 90% at steady-state levels. The sustained reduction in intraprostatic DHT leads to a regression of enlarged prostate tissue, thereby decreasing mechanical obstruction of the urethra and improving urinary dynamics over prolonged therapy.

Dosing schedule

management of BPH typically involves an oral dose of 0.5 mg administered once daily. The capsule or tablet should be swallowed whole with water and must not be chewed, crushed, or opened, as direct contact with the capsule contents may cause irritation of the oropharyngeal mucosa. Veltride may be ingested with or without food, as food co-administration does not significantly alter overall systemic bioavailability. Adherence to a consistent daily schedule is essential because therapeutic benefit develops gradually over extended periods. Clinical response should be evaluated after 3 to 6 months of continuous administration to determine long-term treatment efficacy.

What happens in the body

Following oral administration, peak plasma concentrations of dutasteride are achieved within 1 to 3 hours. Absolute bioavailability is approximately 60%, subject to minor individual variations. The drug exhibits high binding to plasma proteins, exceeding 99% binding to serum albumin and alpha-1 acid glycoprotein. Dutasteride undergoes extensive hepatic metabolism mediated primarily by the cytochrome P450 enzymes CYP3A4 and CYP3A5, yielding active and inactive metabolites. The terminal elimination half-life of dutasteride is exceptionally long, reaching approximately 5 weeks at steady state. Clearance occurs predominantly through the fecal route, with less than 0.1% of an administered dose excreted unchanged in urine.

Compatibility with other medicines

Co-administration of Veltride with strong or moderate inhibitors of the CYP3A4 enzyme system–such as ritonavir, ketoconazole, itraconazole, diltiazem, verapamil, and ciprofloxacin–can result in elevated plasma concentrations of dutasteride due to decreased metabolic clearance. Caution and close clinical monitoring are recommended when initiating long-term therapy with concurrent CYP3A4 inhibitors. In pharmacokinetic trials, no clinically significant drug-drug interactions were observed when combined with warfarin, digoxin, cholestyramine, or sildenafil. Patients must disclose all prescription, over-the-counter, and herbal preparations to their physician before initiating therapy.

Adverse reactions

Adverse reactions associated with Veltride are primarily linked to androgen suppression. Commonly reported events in clinical trials include erectile dysfunction, decreased libido, ejaculation disorders (such as reduced ejaculate volume), and gynecomastia (breast enlargement or tenderness). The incidence of sexual side effects is highest during the first year of treatment and frequently decreases in frequency during continued long-term therapy. Hypersensitivity reactions, including localized skin rash, pruritus, urticaria, and localized angioedema, occur less frequently. Patients experiencing persistent or severe allergic manifestations should seek immediate medical evaluation.

Important precautions

Patients receiving Veltride must undergo baseline screening for prostate cancer prior to initiation and periodically throughout therapy. Dutasteride administration reduces serum Prostate-Specific Antigen (PSA) levels by approximately 50% after 6 months of continuous use; therefore, any PSA value measured during treatment must be interpreted relative to this baseline reduction. An increasing PSA level while on treatment may indicate non-compliance or an underlying prostate malignancy. Clinical trials evaluating 5-alpha reductase inhibitors demonstrated a small, statistically significant increase in the diagnosis of high-grade prostate cancer. Patients with moderate to severe hepatic impairment should be monitored closely due to the drug’s extensive liver metabolism.

Special populations

Veltride is strictly contraindicated in female patients, pediatric populations, and adolescents. Women who are pregnant or may become pregnant must avoid touching crushed, broken, or leaking capsules. Transdermal absorption of dutasteride poses a established teratogenic risk to the developing male fetus, potentially leading to structural abnormalities of external genitalia. For elderly patients with normal age-related renal clearance, no dose adjustment is required. Dose modification is similarly unnecessary in patients with renal impairment, as less than 0.1% of the drug is excreted via the kidneys.

What you may notice early on

During the initial weeks of treatment, subjective changes in urinary symptoms may not be immediately apparent. Because reduction of prostate tissue volume requires sustained inhibition of dihydrotestosterone, clinical improvement generally unfolds over several months. Some individuals observe mild improvements in urinary flow within 3 to 4 weeks, but maximum therapeutic response typically requires at least 6 months of unbroken daily dosing. Halting therapy prematurely can result in a return of prostate enlargement and recurrent lower urinary tract symptoms.

If you skip a dose

If a dose of Veltride is missed, it should be taken as soon as remembered on the same day. However, if the time is close to the next scheduled administration, the missed dose should be skipped entirely, and the regular daily schedule resumed. Patients must not double the daily dose to make up for a missed tablet or capsule. Because of the prolonged elimination half-life of dutasteride, missing a single dose does not abruptly compromise therapeutic plasma concentrations, though routine daily adherence remains vital for stable therapeutic outcomes.

Practical tips

Store Veltride in its original packaging at controlled room temperature, away from excessive moisture, direct sunlight, and heat sources. Keep the medication securely out of reach of children and pets. Blood donation is strictly prohibited during treatment with Veltride and for at least 6 months following the final dose to prevent blood transfusions containing residual drug from being administered to pregnant women. Maintain regular medical appointments in cities such as Boston, Chicago, or elsewhere to track ongoing prostate health metrics.

Common questions

How long does it take for Veltride to produce measurable improvements in urinary symptoms?

Clinical response varies among individuals. While preliminary improvement may appear within 3 to 6 weeks, full therapeutic benefit usually requires 6 months of daily continuous use to allow sufficient regression of enlarged prostate tissue.

Why is blood donation prohibited during treatment with Veltride?

Dutasteride has a extended elimination half-life of about 5 weeks. A mandatory 6-month post-treatment waiting period prevents donated blood containing residual drug levels from being transfused into pregnant female recipients, protecting fetal development.

Is it necessary to take Veltride with food?

No. Veltride can be ingested either with or without food. Dietary intake does not clinically alter the extent of systemic absorption or bioavailability of the active drug.

What should I do if a capsule breaks or leaks?

If a capsule is damaged or leaking, avoid direct skin contact. Women of childbearing potential must not handle damaged capsules. Wash the affected skin surface thoroughly with soap and water if accidental contact occurs.

Does Veltride permanently alter Prostate-Specific Antigen (PSA) values?

Veltride predictable lowers serum PSA concentration by about 50% after 6 months of daily use. Healthcare providers adjust measured PSA values upward during routine prostate cancer screening to account for this medication-induced decline.

Dispensed in accordance with applicable federal and state regulations within the United States market.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

0.5 mg

Package

30 tabs

,

60 tabs

,

90 tabs

Ενεργός Ουσία